Articles with public access mandates - Craig GedyeLearn more
Not available anywhere: 6
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
Mandates: National Health and Medical Research Council, Australia
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
L Albiges, H Gurney, V Atduev, C Suarez, MA Climent, D Pook, ...
The Lancet Oncology 24 (8), 881-891, 2023
Mandates: US National Institutes of Health
Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities
C Gedye, A Van der Westhuizen, T John
Internal medicine journal 45 (7), 696-701, 2015
Mandates: National Health and Medical Research Council, Australia
Research perspective on utilizing and valuing tumor biobanks
A Rush, L Matzke, S Cooper, C Gedye, JA Byrne, PH Watson
Biopreservation and biobanking 17 (3), 219-229, 2019
Mandates: Canadian Institutes of Health Research
ENZA‐p trial protocol: a randomized phase II trial using prostate‐specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration …
L Emmett, S Subramaniam, AM Joshua, M Crumbaker, A Martin, ...
BJU international 128 (5), 642-651, 2021
Mandates: National Health and Medical Research Council, Australia, Medical Research …
Patients’ experiences and preferences for opt‐in models and health professional involvement in biobanking consent: A cross‐sectional survey of Australian cancer outpatients
EA Fradgley, SE Chong, ME Cox, C Gedye, CL Paul
Asia‐Pacific Journal of Clinical Oncology 15 (1), 31-37, 2019
Mandates: National Health and Medical Research Council, Australia
Available somewhere: 31
An immune atlas of clear cell renal cell carcinoma
S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ...
Cell 169 (4), 736-749. e18, 2017
Mandates: Swiss National Science Foundation, US National Institutes of Health …
Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells
JM Stewart, PA Shaw, C Gedye, MQ Bernardini, BG Neel, LE Ailles
Proceedings of the National Academy of Sciences 108 (16), 6468-6473, 2011
Mandates: Canadian Institutes of Health Research, Ontario Institute for Cancer Research
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP …
JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ...
The Lancet Oncology 23 (11), 1389-1397, 2022
Mandates: US Department of Defense, National Health and Medical Research Council …
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
AB Lassman, SL Pugh, TJC Wang, K Aldape, HK Gan, M Preusser, ...
Neuro-oncology 25 (2), 339-350, 2023
Mandates: US National Institutes of Health
Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity
CA Gedye, A Hussain, J Paterson, A Smrke, H Saini, D Sirskyj, K Pereira, ...
PloS one 9 (8), e105602, 2014
Mandates: National Health and Medical Research Council, Australia, Canadian Institutes …
Tumor genomic testing for> 4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)
M Hussain, C Corcoran, C Sibilla, K Fizazi, F Saad, N Shore, S Sandhu, ...
Clinical Cancer Research 28 (8), 1518-1530, 2022
Mandates: National Institute for Health Research, UK
Human perforin mutations and susceptibility to multiple primary cancers
JA Trapani, KYT Thia, M Andrews, ID Davis, C Gedye, P Parente, ...
Oncoimmunology 2 (4), e24185, 2013
Mandates: National Health and Medical Research Council, Australia
Overall survival with [177Lu] Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase …
MS Hofman, L Emmett, S Sandhu, A Iravani, JP Buteau, AM Joshua, ...
The Lancet Oncology 25 (1), 99-107, 2024
Mandates: National Health and Medical Research Council, Australia, Medical Research …
Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
L Khoja, M Kibiro, UR Metser, C Gedye, D Hogg, MO Butler, EG Atenafu, ...
British Journal of Cancer 115 (10), 1186-1192, 2016
Mandates: Canadian Institutes of Health Research
Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer
F Afrin, M Chi, AL Eamens, RJ Duchatel, AM Douglas, J Schneider, ...
Cancers 12 (4), 1033, 2020
Mandates: National Health and Medical Research Council, Australia
The Ludwig institute for cancer research Melbourne melanoma cell line panel
A Behren, M Anaka, PH Lo, LJ Vella, ID Davis, J Catimel, T Cardwell, ...
Pigment cell & melanoma research 26 (4), 597-600, 2013
Mandates: National Health and Medical Research Council, Australia, UK Medical Research …
Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
L Khoja, EG Atenafu, Q Ye, C Gedye, M Chappell, D Hogg, MO Butler, ...
Oncology letters 11 (2), 1581-1585, 2016
Mandates: National Health and Medical Research Council, Australia, Canadian Institutes …
Canadian guideline on genetic screening for hereditary renal cell cancers
MN Reaume, GE Graham, E Tomiak, S Kamel-Reid, MAS Jewett, ...
Canadian Urological Association Journal 7 (9-10), 319, 2013
Mandates: Canadian Institutes of Health Research
Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and …
NC Lobo, C Gedye, AJ Apostoli, KR Brown, J Paterson, N Stickle, ...
BMC cancer 16, 1-15, 2016
Mandates: National Health and Medical Research Council, Australia, Canadian Institutes …
Publication and funding information is determined automatically by a computer program